Xponance Inc. Buys 2,661 Shares of Teladoc Health, Inc. (NYSE:TDOC)

Xponance Inc. raised its position in shares of Teladoc Health, Inc. (NYSE:TDOC) by 23.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,861 shares of the health services provider’s stock after acquiring an additional 2,661 shares during the period. Xponance Inc.’s holdings in Teladoc Health were worth $126,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TDOC. Point72 Asset Management L.P. increased its holdings in shares of Teladoc Health by 57.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 8,366,295 shares of the health services provider’s stock worth $76,803,000 after purchasing an additional 3,063,172 shares during the period. Geode Capital Management LLC grew its holdings in shares of Teladoc Health by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 3,925,167 shares of the health services provider’s stock worth $36,042,000 after purchasing an additional 56,864 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Teladoc Health by 18.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,443,713 shares of the health services provider’s stock worth $22,213,000 after buying an additional 384,528 shares during the last quarter. Invenomic Capital Management LP increased its holdings in Teladoc Health by 155.2% during the 3rd quarter. Invenomic Capital Management LP now owns 1,474,337 shares of the health services provider’s stock valued at $13,534,000 after purchasing an additional 896,552 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. bought a new position in shares of Teladoc Health in the third quarter valued at about $11,291,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Adam C. Vandervoort sold 11,011 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $8.42, for a total transaction of $92,712.62. Following the completion of the transaction, the insider now directly owns 64,308 shares in the company, valued at $541,473.36. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.95% of the company’s stock.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $8.12 on Friday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -1.41 and a beta of 1.27. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. Teladoc Health, Inc. has a 52 week low of $6.76 and a 52 week high of $15.27. The company has a 50-day simple moving average of $10.34 and a 200 day simple moving average of $9.79.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The firm had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. On average, sell-side analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TDOC shares. Oppenheimer reduced their price objective on Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Bank of America upped their target price on shares of Teladoc Health from $11.50 to $13.50 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Royal Bank of Canada raised their price target on Teladoc Health from $11.00 to $12.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Piper Sandler reduced their target price on shares of Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group decreased their price target on shares of Teladoc Health from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Eleven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.26.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.